These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11310719)

  • 1. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.
    Oo C; Barrett J; Hill G; Mann J; Dorr A; Dutkowski R; Ward P
    Paediatr Drugs; 2001; 3(3):229-36. PubMed ID: 11310719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.
    Li W; Escarpe PA; Eisenberg EJ; Cundy KC; Sweet C; Jakeman KJ; Merson J; Lew W; Williams M; Zhang L; Kim CU; Bischofberger N; Chen MS; Mendel DB
    Antimicrob Agents Chemother; 1998 Mar; 42(3):647-53. PubMed ID: 9517946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Observational Study on the Pharmacokinetics of Oseltamivir in Lactating Influenza Patients.
    Fodor E; Nagy RN; Nógrádi A; Toovey S; Kamal MA; Vadász P; Bencsik P; Görbe A; Ferdinandy P
    Clin Pharmacol Ther; 2024 Feb; 115(2):318-323. PubMed ID: 37975276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach.
    Kamal MA; Lien KY; Robson R; Subramoney V; Clinch B; Rayner CR; Gibiansky L
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6774-81. PubMed ID: 26282419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.
    Jittamala P; Pukrittayakamee S; Tarning J; Lindegardh N; Hanpithakpong W; Taylor WR; Lawpoolsri S; Charunwattana P; Panapipat S; White NJ; Day NP
    Antimicrob Agents Chemother; 2014; 58(3):1615-21. PubMed ID: 24366750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza.
    Wang Y; Zhong W; Salam A; Tarning J; Zhan Q; Huang JA; Weng H; Bai C; Ren Y; Yamada K; Wang D; Guo Q; Fang Q; Tsutomu S; Zou X; Li H; Gillesen A; Castle L; Chen C; Li H; Zhen J; Lu B; Duan J; Guo L; Jiang J; Cao R; Fan G; Li J; Hayden FG; Wang C; Horby P; Cao B
    EBioMedicine; 2020 Dec; 62():103125. PubMed ID: 33232871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RDN for the treatment of influenza in children: a randomized, double-blinded, parallel-controlled clinical trial.
    Yang S; Xie YM; Wang LX
    BMC Complement Med Ther; 2023 Jul; 23(1):255. PubMed ID: 37474974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.
    Davies BE
    J Antimicrob Chemother; 2010 Apr; 65 Suppl 2(Suppl 2):ii5-ii10. PubMed ID: 20215135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules.
    Winiarski AP; Infeld MH; Tscherne R; Bachynsky M; Rucki R; Nagano-Mate K
    J Am Pharm Assoc (2003); 2007; 47(6):747-55. PubMed ID: 18032138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.
    Oo C; Hill G; Dorr A; Liu B; Boellner S; Ward P
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):411-5. PubMed ID: 12910331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo stability of oseltamivir within a bioequivalence trial.
    Grigoriev A; Borisova I; Yaroshenko I; Sidorova A
    Anal Bioanal Chem; 2016 May; 408(14):3891-7. PubMed ID: 27002612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.
    Jefferson T; Jones M; Doshi P; Spencer EA; Onakpoya I; Heneghan CJ
    BMJ; 2014 Apr; 348():g2545. PubMed ID: 24811411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuraminidase inhibitors for preventing and treating influenza in adults and children.
    Jefferson T; Jones MA; Doshi P; Del Mar CB; Hama R; Thompson MJ; Spencer EA; Onakpoya I; Mahtani KR; Nunan D; Howick J; Heneghan CJ
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD008965. PubMed ID: 24718923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oseltamivir oral suspension and capsules are bioequivalent for the active metabolite in healthy adult volunteers.
    Lennon S; Barrett J; Kirkpatrick C; Rayner C
    Int J Clin Pharmacol Ther; 2009 Aug; 47(8):539-48. PubMed ID: 19640363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis.
    Robson R; Buttimore A; Lynn K; Brewster M; Ward P
    Nephrol Dial Transplant; 2006 Sep; 21(9):2556-62. PubMed ID: 16799169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oseltamivir: a clinical and pharmacological perspective.
    Doucette KE; Aoki FY
    Expert Opin Pharmacother; 2001 Oct; 2(10):1671-83. PubMed ID: 11825310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.
    Hayden FG; Belshe R; Villanueva C; Lanno R; Hughes C; Small I; Dutkowski R; Ward P; Carr J
    J Infect Dis; 2004 Feb; 189(3):440-9. PubMed ID: 14745701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of antiviral drugs for seasonal influenza: Foundation document for practitioners-Update 2019.
    Aoki FY; Allen UD; Mubareka S; Papenburg J; Stiver HG; Evans GA
    J Assoc Med Microbiol Infect Dis Can; 2019 Jun; 4(2):60-82. PubMed ID: 36337743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovated formulation of oseltamivir powder for suspension with stability study after reconstitution using a developed ion-pair reversed phase high-performance liquid chromatography method.
    Hasson KJ
    J Adv Pharm Technol Res; 2022; 13(3):177-181. PubMed ID: 35935702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.
    Dubinsky S; Watt K; Saleeb S; Ahmed B; Carter C; Yeung CHT; Edginton A
    Clin Pharmacokinet; 2022 Feb; 61(2):189-229. PubMed ID: 34846703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.